Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Wants Resubmission On PAVmed Carpal Tunnel Syndrome 510(k)

Executive Summary

Device manufacturer PAVmed is planning to resubmit a 510(k) for its CarpX product to treat carpal tunnel syndrome after US FDA said it couldn’t reach a consensus on approval.

You may also be interested in...



Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.

Industry And Investors Ponder Legacy Of Theranos Scandal

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Attorneys Mull Takeaways From Conviction Of Theranos Founder Holmes

Elizabeth Holmes has been convicted on four counts of investor fraud. Two attorneys who followed the case spoke to Medtech Insight about what happened – and what it could mean for industry as a whole.

Topics

Related Companies

UsernamePublicRestriction

Register

MT123186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel